CD8A and neoplasm: We demonstrate here in mice that a triple combination of a CD122-directed IL-2 derivative, RT, and anti-PD1 may act as a rather potent personalized in situ vaccine and tremendously increase the number of tumor-specific CD8+ T cells in the blood circulation.